You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSuprofen
Accession NumberDB00870  (APRD00230)
TypeSmall Molecule
GroupsApproved, Withdrawn
DescriptionAn ibuprofen-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic. It is no longer approved for use in the United States.
Structure
Thumb
Synonyms
(+-)-2-(P-(2-Thenoyl)phenyl)propionic acid
2-(4-(2-Thenoyl)phenyl)propionsaeure
2-[4-(Thiophene-2-carbonyl)-phenyl]-propionic acid
4-(2-Thenoyl)hydratropsaeure
alpha-Methyl-4-(2-thienylcarbonyl)benzeneacetic acid
P-2-Thenoylhydratropic acid
PROFENAL
Suprofen
Suprofène
Suprofene
Suprofeno
Suprofenum
SUTOPROFEN
External Identifiers
  • R 25061
  • TN 762
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ProfenalJanssen Pharmaceuticals
SrendamPola Pharma
SulprotinTaiyo Pharmaceutical
TopalgicAlfresa Pharma
Brand mixturesNot Available
SaltsNot Available
Categories
UNII988GU2F9PE
CAS number40828-46-4
WeightAverage: 260.308
Monoisotopic: 260.05071494
Chemical FormulaC14H12O3S
InChI KeyInChIKey=MDKGKXOCJGEUJW-UHFFFAOYSA-N
InChI
InChI=1S/C14H12O3S/c1-9(14(16)17)10-4-6-11(7-5-10)13(15)12-3-2-8-18-12/h2-9H,1H3,(H,16,17)
IUPAC Name
2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid
SMILES
CC(C(O)=O)C1=CC=C(C=C1)C(=O)C1=CC=CS1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpropanoic acids. These are compounds with a structure containing a benzene ring conjugated to a propanoic acid.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassPhenylpropanoic acids
Sub ClassNot Available
Direct ParentPhenylpropanoic acids
Alternative Parents
Substituents
  • 2-phenylpropanoic-acid
  • Phenylacetate
  • Monoterpenoid
  • Monocyclic monoterpenoid
  • Aromatic monoterpenoid
  • P-cymene
  • Acetophenone
  • Aryl ketone
  • Thiophene carboxylic acid or derivatives
  • Benzoyl
  • Benzenoid
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Thiophene
  • Ketone
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed as eye drops to inhibit the miosis (pupil constriction) that may occur during ocular surgery.
PharmacodynamicsSuprofen is a non-steroidal anti-inflammatory analgesic and antipyretic. Ophthalmic anti-inflammatory medicines are used in the eye to lessen problems that can occur during or after some kinds of eye surgery. Sometimes, the pupil of the eye gets smaller during an operation (pupil constriction), making it more difficult for the surgeon to reach some areas of the eye. Suprofen is used to help prevent this.
Mechanism of actionSuprofen binds to the cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) isoenzymes, preventing the synthesis of prostaglandins and reducing the inflammatory response. Cyclooxygenase catalyses the formation of prostaglandins and thromboxane from arachidonic acid (itself derived from the cellular phospholipid bilayer by phospholipase A2). Prostaglandins act (among other things) as messenger molecules in the process of inflammation. The overall result is a reduction in pain and inflammation in the eyes and the prevention of pupil constriction during surgery. Normally trauma to the anterior segment of the eye (especially the iris) increases endogenous prostaglandin synthesis which leads to constriction of the iris sphincter.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding20%
Metabolism

Primarily hepatic (mainly via cytochrome P450 isozyme 2C9).

SubstrateEnzymesProduct
Suprofen
Suprofen S-oxideDetails
Suprofen
Thiophene-4,5-epoxideDetails
Suprofen
Suprofen glucuronideDetails
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySymptoms of overdose include bleeding in the eye or redness or swelling of the eye or the eyelid, blurred vision or other change in vision, fever or chills, itching or tearing, nausea or vomiting, pain, sensitivity to light, shortness of breath, sticky or matted eyelashes, swelling of face, throbbing pain, tightness in chest, troubled breathing, and wheezing.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Suprofen Action PathwayDrug actionSMP00101
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9927
Blood Brain Barrier+0.9289
Caco-2 permeable+0.6039
P-glycoprotein substrateNon-substrate0.7298
P-glycoprotein inhibitor INon-inhibitor0.9534
P-glycoprotein inhibitor IINon-inhibitor0.9664
Renal organic cation transporterNon-inhibitor0.8998
CYP450 2C9 substrateNon-substrate0.6293
CYP450 2D6 substrateNon-substrate0.9226
CYP450 3A4 substrateNon-substrate0.8098
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.8607
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.8958
CYP450 3A4 inhibitorNon-inhibitor0.9526
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8682
Ames testNon AMES toxic0.9398
CarcinogenicityNon-carcinogens0.7568
BiodegradationReady biodegradable0.7714
Rat acute toxicity3.1892 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9869
hERG inhibition (predictor II)Non-inhibitor0.9716
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Alcon laboratories inc
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point124.3 °CPhysProp
water solubilitylimited solubilityNot Available
logP2.2Not Available
pKa3.91MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.0422 mg/mLALOGPS
logP3.16ALOGPS
logP3.53ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)4.01ChemAxon
pKa (Strongest Basic)-7.8ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area54.37 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity69.41 m3·mol-1ChemAxon
Polarizability26.84 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesM01AE07
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (50.8 KB)
Interactions
Drug Interactions
Drug
AbciximabSuprofen may increase the anticoagulant activities of Abciximab.
AbirateroneThe metabolism of Suprofen can be decreased when combined with Abiraterone.
AcebutololSuprofen may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Suprofen is combined with Aceclofenac.
AcenocoumarolSuprofen may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Suprofen is combined with Acetylsalicylic acid.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Suprofen.
Alendronic acidThe risk or severity of adverse effects can be increased when Suprofen is combined with Alendronic acid.
AliskirenSuprofen may decrease the antihypertensive activities of Aliskiren.
AlprenololSuprofen may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Suprofen.
AmikacinSuprofen may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideSuprofen may decrease the antihypertensive activities of Amiloride.
AmiodaroneThe metabolism of Suprofen can be decreased when combined with Amiodarone.
AncrodSuprofen may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Suprofen is combined with Antipyrine.
Antithrombin III humanSuprofen may increase the anticoagulant activities of Antithrombin III human.
ApixabanSuprofen may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Suprofen is combined with Apremilast.
AprepitantThe metabolism of Suprofen can be increased when combined with Aprepitant.
ArdeparinSuprofen may increase the anticoagulant activities of Ardeparin.
ArgatrobanSuprofen may increase the anticoagulant activities of Argatroban.
ArotinololSuprofen may decrease the antihypertensive activities of Arotinolol.
AtenololSuprofen may decrease the antihypertensive activities of Atenolol.
AzapropazoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Suprofen is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Suprofen.
BalsalazideSuprofen may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Suprofen.
BecaplerminSuprofen may increase the anticoagulant activities of Becaplermin.
BefunololSuprofen may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Suprofen.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Suprofen.
BenoxaprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Benoxaprofen.
BetaxololSuprofen may decrease the antihypertensive activities of Betaxolol.
BevantololSuprofen may decrease the antihypertensive activities of Bevantolol.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Suprofen.
BisoprololSuprofen may decrease the antihypertensive activities of Bisoprolol.
BivalirudinSuprofen may increase the anticoagulant activities of Bivalirudin.
BopindololSuprofen may decrease the antihypertensive activities of Bopindolol.
BromfenacThe risk or severity of adverse effects can be increased when Suprofen is combined with Bromfenac.
BufuralolSuprofen may decrease the antihypertensive activities of Bufuralol.
BumetanideSuprofen may decrease the diuretic activities of Bumetanide.
BupranololSuprofen may decrease the antihypertensive activities of Bupranolol.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Suprofen.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Suprofen.
CapecitabineThe metabolism of Suprofen can be decreased when combined with Capecitabine.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Suprofen.
CarbamazepineThe metabolism of Suprofen can be increased when combined with Carbamazepine.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Suprofen.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Suprofen.
CarteololSuprofen may decrease the antihypertensive activities of Carteolol.
CarvedilolSuprofen may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Suprofen is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Suprofen.
CeliprololSuprofen may decrease the antihypertensive activities of Celiprolol.
CeritinibThe serum concentration of Suprofen can be increased when it is combined with Ceritinib.
CertoparinSuprofen may increase the anticoagulant activities of Certoparin.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Suprofen.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Suprofen.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Suprofen.
CholecalciferolThe metabolism of Suprofen can be decreased when combined with Cholecalciferol.
CholestyramineCholestyramine can cause a decrease in the absorption of Suprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Suprofen.
Citric AcidSuprofen may increase the anticoagulant activities of Citric Acid.
ClodronateThe risk or severity of adverse effects can be increased when Suprofen is combined with Clodronate.
ClonixinThe risk or severity of adverse effects can be increased when Suprofen is combined with Clonixin.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Suprofen.
ClotrimazoleThe metabolism of Suprofen can be decreased when combined with Clotrimazole.
ColesevelamColesevelam can cause a decrease in the absorption of Suprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Suprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.
CyclosporineSuprofen may increase the nephrotoxic activities of Cyclosporine.
CyclosporineThe metabolism of Suprofen can be decreased when combined with Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when Suprofen is combined with D-Limonene.
Dabigatran etexilateSuprofen may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Suprofen can be decreased when it is combined with Dabrafenib.
DalteparinSuprofen may increase the anticoagulant activities of Dalteparin.
DanaparoidSuprofen may increase the anticoagulant activities of Danaparoid.
DaunorubicinSuprofen may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe risk or severity of adverse effects can be increased when Suprofen is combined with Deferasirox.
DelavirdineThe metabolism of Suprofen can be decreased when combined with Delavirdine.
DesirudinSuprofen may increase the anticoagulant activities of Desirudin.
DesmopressinThe risk or severity of adverse effects can be increased when Suprofen is combined with Desmopressin.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Suprofen.
DextranSuprofen may increase the anticoagulant activities of Dextran.
Dextran 40Suprofen may increase the anticoagulant activities of Dextran 40.
Dextran 70Suprofen may increase the anticoagulant activities of Dextran 70.
Dextran 75Suprofen may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Suprofen.
DicoumarolSuprofen may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Suprofen.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Suprofen.
DihydrostreptomycinSuprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Suprofen.
DoxorubicinSuprofen may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DrospirenoneSuprofen may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Suprofen is combined with Droxicam.
Edetic AcidSuprofen may increase the anticoagulant activities of Edetic Acid.
EdoxabanSuprofen may increase the anticoagulant activities of Edoxaban.
EfavirenzThe metabolism of Suprofen can be decreased when combined with Efavirenz.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Suprofen.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Suprofen.
EnoxaparinSuprofen may increase the anticoagulant activities of Enoxaparin.
EpirizoleThe risk or severity of adverse effects can be increased when Suprofen is combined with Epirizole.
EpirubicinSuprofen may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneSuprofen may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Suprofen.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Suprofen.
EsmololSuprofen may decrease the antihypertensive activities of Esmolol.
Etacrynic acidSuprofen may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Suprofen.
Ethyl biscoumacetateSuprofen may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Suprofen is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Suprofen.
EtofenamateThe risk or severity of adverse effects can be increased when Suprofen is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Suprofen is combined with Etoricoxib.
EtravirineThe metabolism of Suprofen can be decreased when combined with Etravirine.
Evening primrose oilThe risk or severity of adverse effects can be increased when Suprofen is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Suprofen is combined with exisulind.
FenbufenThe risk or severity of adverse effects can be increased when Suprofen is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Suprofen.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Suprofen.
FloxuridineThe metabolism of Suprofen can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Suprofen can be decreased when combined with Fluconazole.
FlunixinThe risk or severity of adverse effects can be increased when Suprofen is combined with Flunixin.
FluorouracilThe metabolism of Suprofen can be decreased when combined with Fluorouracil.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Suprofen.
FluvastatinThe metabolism of Suprofen can be decreased when combined with Fluvastatin.
FluvoxamineThe metabolism of Suprofen can be decreased when combined with Fluvoxamine.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Suprofen.
Fondaparinux sodiumSuprofen may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Suprofen.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Suprofen.
FosphenytoinThe metabolism of Suprofen can be increased when combined with Fosphenytoin.
FramycetinSuprofen may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideSuprofen may decrease the diuretic activities of Furosemide.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Suprofen.
GemfibrozilThe metabolism of Suprofen can be decreased when combined with Gemfibrozil.
GentamicinSuprofen may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
HaloperidolThe risk or severity of adverse effects can be increased when Suprofen is combined with Haloperidol.
HeparinSuprofen may increase the anticoagulant activities of Heparin.
HirulogSuprofen may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Suprofen is combined with HMPL-004.
HydralazineSuprofen may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Suprofen.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Suprofen.
Hygromycin BSuprofen may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Suprofen is combined with Ibandronate.
IbuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Suprofen is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Suprofen is combined with Icatibant.
IdarubicinSuprofen may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Suprofen.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Suprofen.
IndenololSuprofen may decrease the antihypertensive activities of Indenolol.
IndinavirThe metabolism of Suprofen can be decreased when combined with Indinavir.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Suprofen.
IndoprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Suprofen.
IsoxicamThe risk or severity of adverse effects can be increased when Suprofen is combined with Isoxicam.
KanamycinSuprofen may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Kebuzone.
KetoconazoleThe metabolism of Suprofen can be decreased when combined with Ketoconazole.
KetoprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Suprofen.
LabetalolSuprofen may decrease the antihypertensive activities of Labetalol.
LeflunomideThe risk or severity of adverse effects can be increased when Suprofen is combined with Leflunomide.
LepirudinSuprofen may increase the anticoagulant activities of Lepirudin.
LevobunololSuprofen may decrease the antihypertensive activities of Levobunolol.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Suprofen.
LithiumThe serum concentration of Lithium can be increased when it is combined with Suprofen.
LornoxicamThe risk or severity of adverse effects can be increased when Suprofen is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Suprofen.
LovastatinThe metabolism of Suprofen can be decreased when combined with Lovastatin.
LoxoprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Suprofen.
LumacaftorThe serum concentration of Suprofen can be decreased when it is combined with Lumacaftor.
LumiracoxibThe risk or severity of adverse effects can be increased when Suprofen is combined with Lumiracoxib.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Suprofen is combined with Magnesium salicylate.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Suprofen.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Suprofen is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Suprofen.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Suprofen.
MesalazineSuprofen may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Suprofen.
MetamizoleThe risk or severity of adverse effects can be increased when Suprofen is combined with Metamizole.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Suprofen.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Suprofen.
MetipranololSuprofen may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Suprofen.
MetoprololSuprofen may decrease the antihypertensive activities of Metoprolol.
MetrizamideSuprofen may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MifepristoneThe serum concentration of Suprofen can be increased when it is combined with Mifepristone.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Suprofen.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Suprofen.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Suprofen.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Suprofen.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Suprofen is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Suprofen.
NadololSuprofen may decrease the antihypertensive activities of Nadolol.
NadroparinSuprofen may increase the anticoagulant activities of Nadroparin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Suprofen.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Suprofen.
NCX 4016The risk or severity of adverse effects can be increased when Suprofen is combined with NCX 4016.
NeomycinSuprofen may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Suprofen is combined with Nepafenac.
NetilmicinSuprofen may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
NicardipineThe metabolism of Suprofen can be decreased when combined with Nicardipine.
Niflumic AcidThe risk or severity of adverse effects can be increased when Suprofen is combined with Niflumic Acid.
NimesulideThe risk or severity of adverse effects can be increased when Suprofen is combined with Nimesulide.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Suprofen.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Suprofen.
OlsalazineSuprofen may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Suprofen.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Suprofen is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Suprofen.
OmeprazoleThe metabolism of Suprofen can be decreased when combined with Omeprazole.
OrgoteinThe risk or severity of adverse effects can be increased when Suprofen is combined with Orgotein.
OtamixabanSuprofen may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Suprofen is combined with Oxaprozin.
OxprenololSuprofen may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Oxyphenbutazone.
PamidronateThe risk or severity of adverse effects can be increased when Suprofen is combined with Pamidronate.
ParecoxibThe risk or severity of adverse effects can be increased when Suprofen is combined with Parecoxib.
ParomomycinSuprofen may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PenbutololSuprofen may decrease the antihypertensive activities of Penbutolol.
Pentosan PolysulfateSuprofen may increase the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Suprofen.
PhenindioneSuprofen may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe metabolism of Suprofen can be increased when combined with Phenobarbital.
PhenprocoumonSuprofen may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Suprofen.
PhenytoinThe metabolism of Suprofen can be increased when combined with Phenytoin.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Suprofen.
PindololSuprofen may decrease the antihypertensive activities of Pindolol.
PiretanideSuprofen may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Suprofen is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Suprofen.
PlicamycinSuprofen may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Suprofen.
PractololSuprofen may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Suprofen.
PrimidoneThe metabolism of Suprofen can be increased when combined with Primidone.
ProbenecidThe serum concentration of Suprofen can be increased when it is combined with Probenecid.
PropacetamolThe risk or severity of adverse effects can be increased when Suprofen is combined with Propacetamol.
PropranololSuprofen may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Suprofen.
Protein CSuprofen may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeSuprofen may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when Suprofen is combined with PTC299.
PuromycinSuprofen may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
PyrimethamineThe metabolism of Suprofen can be decreased when combined with Pyrimethamine.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Suprofen.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Suprofen.
QuinineThe metabolism of Suprofen can be decreased when combined with Quinine.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Suprofen.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Suprofen.
ResveratrolThe risk or severity of adverse effects can be increased when Suprofen is combined with Resveratrol.
ReviparinSuprofen may increase the anticoagulant activities of Reviparin.
RibostamycinSuprofen may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RifampicinThe metabolism of Suprofen can be increased when combined with Rifampicin.
RifapentineThe metabolism of Suprofen can be increased when combined with Rifapentine.
RisedronateThe risk or severity of adverse effects can be increased when Suprofen is combined with Risedronate.
RivaroxabanSuprofen may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Suprofen.
SalicylamideThe risk or severity of adverse effects can be increased when Suprofen is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Suprofen is combined with Salicylic acid.
SalsalateThe risk or severity of adverse effects can be increased when Suprofen is combined with Salsalate.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Suprofen.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Suprofen.
SecobarbitalThe metabolism of Suprofen can be increased when combined with Secobarbital.
SeratrodastThe risk or severity of adverse effects can be increased when Suprofen is combined with Seratrodast.
SildenafilThe metabolism of Suprofen can be decreased when combined with Sildenafil.
SorafenibThe metabolism of Suprofen can be decreased when combined with Sorafenib.
SotalolSuprofen may decrease the antihypertensive activities of Sotalol.
SpectinomycinSuprofen may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Suprofen.
SpironolactoneSuprofen may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Suprofen is combined with SRT501.
StreptomycinSuprofen may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinSuprofen may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfadiazineThe metabolism of Suprofen can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Suprofen can be decreased when combined with Sulfamethoxazole.
SulfasalazineSuprofen may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Suprofen.
SulfisoxazoleThe metabolism of Suprofen can be decreased when combined with Sulfisoxazole.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Suprofen.
SulodexideSuprofen may increase the anticoagulant activities of Sulodexide.
TacrolimusSuprofen may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Suprofen.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Suprofen.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Suprofen is combined with Technetium Tc-99m Medronate.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Suprofen.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Suprofen.
TenofovirThe risk or severity of adverse effects can be increased when Suprofen is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Suprofen.
TepoxalinThe risk or severity of adverse effects can be increased when Suprofen is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Suprofen is combined with Teriflunomide.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Suprofen is combined with Tiaprofenic acid.
TicagrelorThe metabolism of Suprofen can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Suprofen can be decreased when combined with Ticlopidine.
TiludronateThe risk or severity of adverse effects can be increased when Suprofen is combined with Tiludronate.
TimololSuprofen may decrease the antihypertensive activities of Timolol.
TobramycinSuprofen may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
TolbutamideThe metabolism of Suprofen can be decreased when combined with Tolbutamide.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Suprofen is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Suprofen.
TorasemideSuprofen may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Suprofen.
TranilastThe risk or severity of adverse effects can be increased when Suprofen is combined with Tranilast.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Suprofen.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Suprofen.
TriamtereneSuprofen may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Suprofen.
TrimethoprimThe metabolism of Suprofen can be decreased when combined with Trimethoprim.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Suprofen is combined with Trisalicylate-choline.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Suprofen.
Valproic AcidThe metabolism of Suprofen can be decreased when combined with Valproic Acid.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Suprofen.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Suprofen.
VoriconazoleThe metabolism of Suprofen can be decreased when combined with Voriconazole.
WarfarinSuprofen may increase the anticoagulant activities of Warfarin.
XimelagatranSuprofen may increase the anticoagulant activities of Ximelagatran.
ZafirlukastThe metabolism of Suprofen can be decreased when combined with Zafirlukast.
ZaltoprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Suprofen.
Zoledronic acidThe risk or severity of adverse effects can be increased when Suprofen is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Suprofen is combined with Zomepirac.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Loll PJ, Picot D, Ekabo O, Garavito RM: Synthesis and use of iodinated nonsteroidal antiinflammatory drug analogs as crystallographic probes of the prostaglandin H2 synthase cyclooxygenase active site. Biochemistry. 1996 Jun 11;35(23):7330-40. [PubMed:8652509 ]
  2. Bender A, Scheiber J, Glick M, Davies JW, Azzaoui K, Hamon J, Urban L, Whitebread S, Jenkins JL: Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. ChemMedChem. 2007 Jun;2(6):861-73. [PubMed:17477341 ]
  3. Llorens O, Perez JJ, Palomer A, Mauleon D: Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71. [PubMed:11885959 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Llorens O, Perez JJ, Palomer A, Mauleon D: Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71. [PubMed:11885959 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-methylumbelliferone, 1-naph...
Gene Name:
UGT1A1
Uniprot ID:
P22309
Molecular Weight:
59590.91 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol suggests it may play an important role in regulating the level and activity of these potent and active estrogen metabolites. Is also active with androsterone, hyodeoxycholic acid and tetrachlorocatechol...
Gene Name:
UGT2B7
Uniprot ID:
P16662
Molecular Weight:
60694.12 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23